Supervised clustering of immunohistochemical markers to distinguish atypical and non-atypical endometrial hyperplasia

References

• Silverberg SG, Mutter GL, Kurman RJ, et al. Tumors of the uterine corpus: epithelial tumors and related lesions. In: Tavassoli FA, Stratton MR, eds. WHO classification of tumors: pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003:221–32
   Google Scholar
• Ferenczy A, Gelfand MM. Hyperplasia vs. neoplasia: two tracks for the endometrium? Contemp OB/GYN 1986;28:79–96
   Google Scholar
• Horn L-C, Schnurrbusch U, Bilek K, et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2004;14:348–53
   PubMed Web of Science ®Google Scholar
• Vassileva V, Millar A, Briollais L, et al. Apoptotic and growth regulatory genes as mutational targets in mismatch repair deficient endometrioid adenocarcinomas of young patients. Oncol Rep 2004;11:931–7
   PubMed Web of Science ®Google Scholar
• Laas E, Ballester M, Cortez A, et al. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer. Gynecol Oncol 2014;133:205–10
   PubMedGoogle Scholar
• Dettling M, Bühlmann P. Finding predictive gene groups from microarray data. J Multivar Anal 2004;90:106–131
   Web of Science ®Google Scholar
• Amalinei C, Cianga C, Balan R, et al. Immunohistochemical analysis of steroid receptors, proliferation markers, apoptosis related molecules, and gelatinases in non-neoplastic and neoplastic endometrium. Ann Anat Anat Anz Off Organ Anat Ges 2011;193:43–55
   PubMedGoogle Scholar
• Kato K, Horiuchi S, Terao Y, et al. Relevance of ER to the development of endometrial hyperplasia and adenocarcinoma. Breast Cancer 1999;6:312–9
   PubMedGoogle Scholar
• Pieczyńska B, Wojtylak S, Zawrocki A, Biernat W. Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray. Pol J Pathol Off J Pol Soc Pathol 2011;62:133–8
   PubMedGoogle Scholar
• Pungal A, Balan R, Cotuţiu C. Hormone receptors and markers in endometrial hyperplasia. Immunohistochemical study. Rev Medico-Chir Soc Medici Şi Nat Din Iaşi 2010;114:180–4
   Google Scholar
• Lebeau A, Grob T, Holst F, et al. Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J Pathol 2008;216:151–7
   PubMedGoogle Scholar
• Graesslin O, Cortez A, Fauvet R, et al. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol Off J Eur Soc Med Oncol ESMO 2006;17:637–45
   PubMedGoogle Scholar
• Uzan C, Cortez A, Dufournet C, et al. Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissues express a different profile of matrix metalloproteinases-2, -3 and -11, and of tissue inhibitor metalloproteinases-1 and -2. Virchows Arch Int J Pathol 2004;445:603–9
   PubMed Web of Science ®Google Scholar
• Määttä M, Soini Y, Liakka A, Autio-Harmainen H. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation. Am J Clin Pathol 2000;114:402–11
   PubMedGoogle Scholar
• Soini Y, Alarakkola E, Autio-Harmainen H. Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 1997;28:220–6
   PubMed Web of Science ®Google Scholar
• Delahanty RJ, Xiang Y-B, Spurdle A, et al. Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2013;22:216–23
   Google Scholar
• Ozkara SK, Corakçi A. FHIT expression in neoplastic, hyperplastic, and normal endometrium. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2005;15:1081–8
   PubMedGoogle Scholar
• Boruban MC, Altundag K, Kilic GS, Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP 2008;17:133–8
   PubMed Web of Science ®Google Scholar
• Farmaki E, Chatzistamou I, Bourlis P, et al. Selection of p53-deficient stromal cells in the tumor microenvironment. Genes Cancer 2012;3:592–8
   PubMedGoogle Scholar
• Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287–90
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403–12
   PubMed Web of Science ®Google Scholar
• Lindahl B, Willén R. Spontaneous endometrial hyperplasia. A prospective, 5 year follow-up of 246 patients after abrasio only, including 380 patients followed-up for 2 years. Anticancer Res 1994;14:2141–6
   PubMedGoogle Scholar
• Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 2001;15:393–405
   PubMed Web of Science ®Google Scholar
• Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812–19
   PubMed Web of Science ®Google Scholar
• Koskas M, Azria E, Walker F, et al. Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res 2012;32:1037–43
   PubMedGoogle Scholar
• Steinbakk A, Gudlaugsson E, Aasprong OG, et al. Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am J Obstet Gynecol 2011;204:357.e1–12
   Google Scholar